Mergers & Acquisitions

Filter

Current filters:

None

Popular Filters

44 to 68 of 894 results

AMRI to buy Oso Biopharmaceuticals Manufacturing for $110 million

AMRI to buy Oso Biopharmaceuticals Manufacturing for $110 million

02-06-2014

USA-based Albany Molecular Research has signed a definitive agreement to acquire all of the outstanding…

Albany Molecular ResearchGenericsMergers & AcquisitionsOso BiopharmaceuticalsProduction

Endo completes sale of early-stage drug discovery portfolio

Endo completes sale of early-stage drug discovery portfolio

02-06-2014

Ireland-headquartered Endo Pharmaceuticals has completed the sale of its branded pharmaceutical drug…

AsanaBioSciencesEndo PharmaceuticalsMergers & AcquisitionsPharmaceutical

Roche to acquire Genia Technologies for up to $350 million

Roche to acquire Genia Technologies for up to $350 million

02-06-2014

Swiss drug major Roche said this morning that it plans to acquire Genia Technologies, a privately held…

Genia TechnologiesMergers & AcquisitionsPharmaceuticalRoche

Valeant goes even further, upping recently sweetened offer for Allergan

Valeant goes even further, upping recently sweetened offer for Allergan

02-06-2014

Even before it received an official response from its takeover target US Botox-maker Allergan, acquisitive…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Forest appeases shareholders over Actavis deal

30-05-2014

US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

28-05-2014

Jordon-based drugmaker Hikma Pharmaceuticals has signed an asset purchase agreement with Ben Venue Laboratories,…

Bedford LaboratoriesBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsUSA

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

Valeant Pharma to sell filler and toxin assets to Nestle for $1.4 billion

28-05-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into an agreement to…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceuticalValeant Pharmaceuticals

Recordati finalizes second tranche of Opalia Pharma acquisition

27-05-2014

Following previous announcements about its M&A activity, Italian drugmaker Recordati has now announced…

GenericsMergers & AcquisitionsOpalia PharmaRecordatiRest of the World

AstraZeneca safe (for now?) as Pfizer walks away from pursuit of the firm

26-05-2014

US pharma giant Pfizer, which has been involved in a controversial pursuit of UK-based AstraZeneca, has…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Indian court ruling lifts temporary stay on Sun Pharma takeover of Ranbaxy

26-05-2014

Indian generics drugmaker Sun Pharmaceuticals’ proposed $3.2 billion acquisition of loss-making rival…

Daiichi SankyoGenericsLegalMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Definitive merger plan between BioAlliance Pharma and Topotarget

Definitive merger plan between BioAlliance Pharma and Topotarget

22-05-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget have confirmed details of…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

Pharmaceutical and life sciences deal volume up 53% in 1st-qtr, sets stage for heightened activity in 2014

21-05-2014

Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume increased 53.1% in the first…

GlobalMergers & AcquisitionsPharmaceutical

Ventrus Biosciences boosted on merger plan with Assembly Pharma

19-05-2014

USA-based Ventrus Biosciences saw its shares leap 9.4% to $1.16 in pre-market trading, as it announced…

Anti-viralsAssembly BiosciencesAssembly PharmaceuticalsBiotechnologyMergers & AcquisitionsVentrus Biosciences

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

19-05-2014

After what must have been a hectic weekend of cross Atlantic activity, the board of Anglo-Swedish drug…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Abbott spends $2.9 billion on CFR Pharma to expand Latin American presence

16-05-2014

US drugmaker Abbott has signed an agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals,…

Abbott LaboratoriesCFR PharmaceuticalsGenericsMergers & AcquisitionsSouth America

Now waiting for next move from Pfizer in AstraZeneca bid

Now waiting for next move from Pfizer in AstraZeneca bid

16-05-2014

With the UK Parliamentary investigation now over – but no report out yet – all eyes are on US pharma…

AstraZenecaMergers & AcquisitionsPfizer

Bayer divests interventional device business for $415 million

15-05-2014

German pharma and life sciences major Bayer has entered into a definitive agreement to sell its interventional…

BayerMergers & AcquisitionsPharmaceutical

Cipla invests $1.5 million for 14.6% stake in USA’s Chase Pharma

14-05-2014

Indian drugmaker Cipla has said it will acquire a 14.6% stake in US-based Chase Pharmaceuticals for $1.5…

Chase PharmaceuticalsCiplaCPC 201Mergers & AcquisitionsNeurologicalPharmaceutical

44 to 68 of 894 results

Back to top